GlassScriptPhysician profile
Patricia A Schechter
NPI 1386641306
$5,718.63
in general payments reported to CMS, 2019-2025
30 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $1,180 · 2021: $1,224 · 2022: $987 · 2023: $735 · 2024: $501 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.95 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $674.34 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $400.92 | 2019-2024 | Mounjaro |
| Allergan, INC. | $358.60 | 2019-2020 | |
| Novo Nordisk INC | $272.11 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $265.27 | 2020-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $258.08 | 2019-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $239.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $216.77 | 2022 | |
| Amgen INC. | $210.88 | 2020-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $162.46 | 2020-2022 | |
| Pfizer INC. | $149.61 | 2019-2025 | |
| Merz North America, INC. | $118.16 | 2019-2023 | Xeomin |
| Radius Health, INC. | $116.23 | 2020-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $79.98 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.05 | 2022-2025 | |
| Alk-Abello, INC | $54.24 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.96 | 2019-2022 | |
| Exact Sciences Corporation | $50.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $39.70 | 2024-2025 | Zenpep |
| Supernus Pharmaceuticals, INC. | $38.44 | 2020 | |
| Mannkind Corporation | $37.33 | 2019 | |
| Almatica Pharma LLC | $37.04 | 2025 | Loreev Xr, Teriparatide |
| Ibsa Pharma INC. | $35.22 | 2022-2024 | Tirosint, Licart |
| Genzyme Corporation | $26.13 | 2024 | |
| Daiichi Sankyo INC. | $17.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.47 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.02 | 2022 | |
| Abbott Laboratories | $14.83 | 2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.